Kexing COVID-19 vaccine has been discontinued and inactivated vaccine is no longer recommended.

On January 10 th, a book called"Stop issuing performance pay scheme for COVID-19 project"The document was circulated on the Internet and signed by Beijing Kexing Zhongwei Biotechnology Co., Ltd., which mentioned that the company’s COVID-19 vaccine has been completely discontinued and the company has no COVID-19 vaccine products for sale at present.

At noon on January 10th, Jimu journalist called the product consultation hotline of Kexing Holding Biotechnology Co., Ltd., and the staff confirmed it.Kexing’s COVID-19 vaccine has been discontinued. If you still need to inject this product, you should ask the local CDC if it is in stock.

It is worth noting that there are still a variety of vaccines for new strains that can be injected in various parts of China.

Kexing COVID-19 vaccine has been discontinued.

Many companies have "got off the bus" before.

According to Jimu News, on January 10th, a document named "Stop Issuing Performance Pay Scheme for COVID-19 Project" was spread on the Internet. The date of signing the scheme was January 9th, and it was stamped with the official seal of Beijing Kexing Zhongwei Biotechnology Co., Ltd., which mentioned that at this stage, the company has stopped production of COVID-19 vaccine and the company has no sales of COVID-19 vaccine products at present, and the company decided to stop issuing performance pay for COVID-19 project for existing employees from January 2024.

Beijing Kexing Zhongwei Biotechnology Co., Ltd. is a subsidiary of Kexing Holding Biotechnology Co., Ltd. At noon on January 10,The staff of the product consultation hotline of Kexing Holding Biotechnology Co., Ltd. confirmed that at present, the COVID-19 vaccine of Kexing of the company has been discontinued. If the product needs to be injected, it is necessary to ask the local CDC if it is in stock.As for the authenticity of the online transmission of "Stop Sending Performance Pay Scheme for COVID-19 Project", the other party said it was unclear, and she was only responsible for product consultation.

In fact, since 2023, a number of companies that have been developing COVID-19 vaccine have either announced a change of direction or stopped investing, or their financial data reflect the "sequela" of "slow sales" of COVID-19 vaccine.

On July 19th, 2023, COVID-19 Microorganism Tianci Factory, one of the three musketeers of domestic mRNA vaccine, suspended its trial operation because there was no demand for vaccine production in the near future. All this was only two and a half years after it obtained the clinical approval of COVID-19 mRNA vaccine in January 2021. At that time, COVID-19 mRNA vaccine of Microorganism was the second domestic COVID-19 mRNA vaccine that entered the clinical stage.

For COVID-19 vaccine, Clover Bio, a Hong Kong-listed company, can be described as "putting all your eggs in one basket". In June, 2022, Clover Bio announced that it would give priority to the allocation of all resources to COVID-19 vaccine project, suspend the investment in the other three clinical pipelines, and reduce the investment in non-COVID-19 projects and new projects. In December 2022, COVID-19 vaccine SCB-2019(CpG 1018/ aluminum adjuvant), a recombinant protein of clover, was put into emergency use in China, and was officially launched for the first time in February 2023.

However, in the semi-annual report of 2023, Clover Bio said that due to the ever-changing and low overall demand for COVID-19 vaccine from China and countries around the world since 2023, the company predicted that COVID-19 vaccine sales in 2023 would not bring meaningful financial contribution. Its vaccine layout turned to respiratory diseases such as RSV and influenza.

In April 2023, the "low-cost operation notice" of Shangyao Kangxinuo was spread on the Internet. The content of the notice shows that it is decided to suspend the production line from April 4 for a period of 180 days. According to Red Star News at that time, the staff of Kangxinuo patient answering hotline introduced that the COVID-19 (vaccine) production line here was temporarily suspended, and there was no problem here at the headquarters. Now the demand for COVID-19 vaccine is not so great, so the production line of Shanghai Kangxinuo COVID-19 (vaccine) has been temporarily stopped, which will not affect other aspects.

Chang Rongshan: Inactivated vaccine is not recommended at present.

In February 2023, a research paper published by domestic researchers in the latest issue of China CDC Weekly stated that,"Although the protective efficacy of the third dose of Kexing inactivated vaccine can be improved to more than 70% within one month after homologous inoculation, its predictive efficacy will gradually decline to less than 50% after six months."

For COVID-19 infected people whose clinical endpoint is "COVID-19’s symptoms", the research results show that after 28 days and 6 months of intensive immunization, the protective effect of three doses of inactivated Kexing vaccine is only about 30% and 10%. Among them,The predicted protective effect of three doses of Kexing inactivated vaccine on Omicron BA.4/5 is even lower.

According to the interface news, virologist Chang Rongshan reminded that,Inactivated vaccine is not recommended at present.It pointed out that the antigenicity of the current epidemic strains has changed greatly, and the effect of inactivated vaccine will be much worse than that of other technological vaccines."It is best to play mRNA vaccine and recombinant protein vaccine."

According to JingJing. com, Xu Yue, an insider of a company that had previously researched and developed vaccines in COVID-19, said, "The research and development cost is one aspect, but the key is that you have developed it, and the virus has mutated, so the research and development speed can’t keep up at all. Vaccine iteration is too fast, and enterprises really can’t afford it, especially the cost of clinical trials. Before it is commercialized, the vaccine will be outdated first. "

Xu Yue told reporters that unlike the flu virus, which may go round and round, Covid-19 has been upgrading all the way, and the popular virus will not come again, and the old virus will not come. Therefore,Once the new COVID-19 vaccine appears, the old vaccine can be said to be "out of the historical stage".

A number of XBB vaccines were approved for use.

However, people’s willingness to vaccinate has obviously decreased.

According to Jingjing.com, on December 28th, 2023, the National Health and Wellness Commission held a press conference on the prevention and treatment of respiratory diseases in winter. Peng Zhibin, director of the Department of Respiratory Infectious Diseases of the Infectious Diseases Management Office of China CDC, said that recently, the spread of JN.1 (the second-generation sub-branch of BA.2.86 mutant in Omicron, Covid-19) has risen rapidly abroad and has become the main epidemic strain.

"The mutant JN.1 belongs to Omicron. Recently, according to the existing evidence, the World Health Organization believes that JN.1 has strong transmission ability and immune escape ability, but there is no evidence to suggest that its pathogenicity is enhanced. Previous infection and vaccination with XBB (Omicron subtype variant strain) vaccine have a cross-effect of immune protection, and it is predicted that the public health risk brought by it is low. " Peng Zhibin said.

At present, many XBB vaccines have been approved for emergency use in China. In June, 2023, the recombinant trivalent Covid-19 (XBB+BA.5+Delta mutant) trimer protein vaccine (hereinafter referred to as WEEK XBB vaccine) was put into emergency use in a certain range. In December, companies such as Shenzhou Cell, Kangxinuo and Livzon Group also announced that COVID-19 vaccine was included in emergency use.

According to the interface news, a domestic vaccine industry practitioner said,At present, the proportion of people’s willingness to vaccinate COVID-19 vaccine has obviously decreased, and the official has not clarified the requirements for vaccination indicators.All this makes "promoting vaccination in COVID-19" less urgent than before, which reduces the motivation of CDC. He said, "For example, if a company has a product approved, as long as it is developed and produced, the company will definitely want to be recognized in the market, and there is no situation in which the company is not enthusiastic. But in fact, from the step of bidding access, many provinces and cities have no enthusiasm. "

Rong Shan, a virologist, also said that the public is not willing to vaccinate COVID-19 vaccine at present. If COVID-19 vaccine is purchased, but not many people come to vaccinate it, it will easily lead to a backlog. Unlike ordinary commodities, vaccines have strict requirements for transportation and storage, and they will be wasted if they are not used after expiration.

Original title: Kexing COVID-19 vaccine has been discontinued! Many companies have long since "got off the bus", inactivated vaccines have not been recommended, and many XBB vaccines have been approved.